Drug Bulletin - February 2006
Help on accessing alternative formats, such
as PDF, MP3 and WAV files, can be obtained in the alternate
format help section.
(340 KB)
Benefit Definitions
Open Benefits
Open benefits are the drugs listed in the Non Insured Health Benefits
(NIHB) Drug Benefit List (DBL) which do not have established criteria
or prior approval requirements.
Limited use Benefits
Limited use drugs are those that have value in specific circumstances,
or which have quantity and frequency limitations. For drugs in
this category, specific criteria must be met to be eligible for
coverage.
Not Added To Formulary
Drugs not added to formulary are those which are not listed in
the NIHB DBL after review by the national Common Drug Review (CDR)
process and/or the Federal Pharmacy and Therapeutics Committee
(FP&T). These drugs will not be added to the NIHB drug list
because published evidence does not support the clinical value
or cost of the drug relative to existing therapies. Coverage may
be considered in special circumstances upon receipt of a completed "Exception
Drugs Request Form". These requests are reviewed on a case
by case basis.
Exclusions
Certain drug therapies for particular conditions do not fall under
the NIHB mandate and will not be provided as benefits under the
NIHB Program (e.g., cosmetic and anti-obesity drugs). As well,
certain drugs will be excluded from the NIHB Program as recommended
by the CDR and the FP&T because published evidence does not
support the clinical value, safety or cost of the drug relative
to existing therapies, or there is insufficient clinical evidence
to support coverage.
Note: The appeal process and the emergency supply policy will
not apply to excluded drugs.
Additions To The Drug Benefit List
Open Benefits
(Effective December 1, 2005)
- Vitamin D, Tablet, 400IU & 1000IU (Generics)
(Effective January 1, 2006)
- Drospirenone 3mg /Ethinyl estradiol 0.03mg, Tablet
(Yasmin® 21 & 28 - Berlex Canada Inc.)
Yasmin® 21 and 28 are indicated for conception control.
- 3. Mirtazapine, Tablet, 15mg, 30mg and 45mg (Remeron®,
Remeron RD® - Organon Canada Limited and generics)
Remeron® and Remeron RD® are indicated for the
symptomatic relief of depressive illness.
New Limited Use Benefits
(Prior approval required)
(Effective March 1, 2006)
- Peginterferon alfa-2a, Injection, 180mcg/vial and Ribavirin,
Tablet, 200mg (Pegasys® RBV™ - Hoffman-LaRoche Limited)
- Peginterferon alfa-2a, Injection, 180mcg/vial (Pegasys® -
Hoffman-LaRoche Limited)
Pegasys® RBV™ and Pegasys® will be
limited use benefits for the treatment of chronic hepatitis C
in patients who are treatment naive, upon the written request
of a hepatologist or other specialist in this area.
- For genotype 1, 4, 5 and 6 an initial 24 week supply will
be approved. A further 24 week supply may be approved if
patient has a viral reduction of at least 2 logs or HCV is
undetectable at 12 weeks (for a total of 48 weeks of treatment).
- For genotype 2 or 3, initial coverage for a maximum of
24 weeks may be approved. Renewals will not be covered.
- Mycophenolate Sodium, Tablet, 180mg and 360mg (Myfortic® -
Novartis Pharmaceuticals Canada Inc.)
Myfortic® will be a limited use benefit for transplant
therapy.
Limited Use Benefits - Revised Criteria
- Peginterferon alfa-2b, Powder for Solution, 50mcg/vial,
80mcg/vial, 100mcg/vial, 120mcg/vial and 150mcg/vial and Ribavirin,
Capsule, 200mg (Pegetron™ - Scherring)
- Peginterferon alfa-2b, Powder for Solution, 74mcg/vial,
118.4mcg/vial, 177.6mcg/vial and 222mcg/vial (Unitron PEG™ -
Scherring
The criteria for Pegetron™ and Unitron PEG™ will
be revised as follows:
For the treatment of chronic hepatitis C in patients who are
treatment naive, upon the written request of a hepatologist or
other specialist in this area.
- For genotype 1, 4, 5 and 6 an initial 24 week supply will
be approved. A further 24 week supply may be approved if
patient has a viral reduction of at least 2 logs or HCV is
undetectable at 12 weeks (for a total of 48 weeks of treatment).
- For genotype 2 or 3, initial coverage for a maximum of
24 weeks may be approved. Renewals will not be covered.
Not Added To Formulary
The following drug products will not be added to the NIHB Drug
Benefit List:
- Risperidone, Powder for Suspension sustainedrelease,
25mg/vial, 37.5mg/vial, and 50mg/vial (Risperdal® Consta® -
Janssen Ortho)
- Gatifloxacin, Ophthalmic Solution, 0.3% (Zymar™ -
Allergan)
- Oxybutynin, Transdermal System, 36mg (Oxytrol™ -
Paladin Labs Inc.)
- Amevive, Injection, 15mg/vial (Amevive™ - Biogen
Idec Canada Inc.)
- Teriparatide, Injection, 250mcg/mL (Forteo™ -
Lily)
The following indications will not be added to the NIHB Drug Benefit
List:
- Imiquimod, Cream, 5% (Aldara® - 3M Pharmaceuticals)
For the treatment of superficial basal cell carcinoma.
- Darbepoetin alfa, Injection, 15mcg, 25mcg, 40mcg, 60mcg,
100mcg, 200mcg, 325mcg and 500mcg (Aranesp™ - Amgen Canada
Inc.)
For the treatment of anemia in patients with nonmyeloid malignancies,
where anemia is due to the effect of concomitantly administered
chemotherapy.
- Etanercept, Powder for Injection, 25mg/vial (Enbrel® -
Amgen Canada Inc.)
For reducing signs and symptoms of active ankylosing spondylitis.
Exclusions
- Paroxetine HCl, Controlled-Release Tablet, 12.5mg and
25mg (Paxil CR™ - GlaxoSmithKline Inc.)
- Ketorolac tromethamine, Ophthalmic Solution, 0.4% (Acular
LS® -
Allergan)
NIHB Deferred Decision On Listing
- Magnesium oxide, citric acid, sodium picosulphate,
Powder for Solution (Pico-Salax™ - Ferring Inc.)
- Dutasteride, Capsule, 0.5mg (Avodart™ - GlaxoSmithKline
Inc.)
- Pegfilgrastim, Injection, 6mg/syringe (Neulasta™ -
Amgen Canada Inc.)
- Fosamprenavir calcium, Tablet, 700mg and Oral Suspension
50mg/mL (Telzir™ - GlazoSmithKline)
- Agalsidase beta, Lyophilized Powder (Fabrazyme® -
Genzyme Canada Inc.)
- Agalsidase alfa, Concentrate for Solution for Infusion,
1mg/mL (Replagal™ - Transkaryotic Therapies Inc.)
- Miglustat, Capsule, 100mg (Zavesca™ - Actelion
Pharmaceuticals Ltd.)
- Laronidase, Solution for Injection (Aldurazyme® -
Genzyme Canada Inc.)
- Enfuvirtide, Lyophilized Powder (Fuzeon® - Hoffman-LaRoche
Limited)
|